| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,1
* Department of Internal Medicine and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan 48109
To whom requests for reprints should be addressed at 1 Department of Human Genetics, University of Michigan Medical School, 5024 Kresge Building II, Ann Arbor, MI 48109–0534. E-mail: brewergj{at}umich.edu
Tetrathiomolybdate, an anticopper drug, has been shown to protect mice against pulmonary fibrosis from bleomycin. Our hypothesis is that it does so by inhibiting fibrosis-inducing cytokines. Indeed, we have good evidence, not yet published, that tetrathiomolybdate inhibits pulmonary levels of transforming growth factor–ß and tumor necrosis factor-
expression in these bleomycin experiments. Herein, we evaluate tetrathiomolybdate’s effectiveness in mitigating hepatitis and fibrosis in mice from the hepatotoxins, concanavalin A and carbon tetrachloride, and its inhibition of cytokines as a possible mechanism. In short-term experiments, concanavalin A elevated serum amino leucine transferase levels several fold, and tetrathiomolybdate completely prevented this increase. In additional experiments, tetrathiomolybdate therapy reversed the elevated serum transaminase levels despite continued concanavalin A injections, with nearly significant serum interleukin-1ß inhibition. Concanavalin A given for 12 weeks produced mild fibrosis, whereas concomitant tetrathiomolybdate treatment resulted in normal histology. Carbon tetrachloride given for 12 weeks resulted in very high serum amino leucine transferase levels, high serum transforming growth factor–ß levels, cirrhosis as seen histologically, and increase in liver hydroxyproline, a measure of fibrosis. Concomitant tetrathiomolybdate partially and significantly protected against increases in amino leucine transferase and transforming growth factor–ß, fully protected against the increase in hydroxyproline, and resulted in normal histology. In conclusion, tetrathiomolybdate protects against the hepatitis and fibrosis produced by these hepatotoxins, probably by inhibiting the excessive increase in inflammatory and fibrotic cytokines.
Key Words: copper • hepatitis • cirrhosis • transforming growth factorß • interleukin-1ß
This article has been cited by other articles:
|
|
 |
|
  C. Zeng, G. Hou, R. Dick, and G. J. Brewer Tetrathiomolybdate Is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes Experimental Biology and Medicine, August 1, 2008; 233(8): 1021 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Song, Z. Song, S. Barve, J. Zhang, T. Chen, M. Liu, G. E. Arteel, G. J. Brewer, and C. J. McClain Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Brewer Iron and Copper Toxicity in Diseases of Aging, Particularly Atherosclerosis and Alzheimer's Disease Experimental Biology and Medicine, February 1, 2007; 232(2): 323 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gong, J. Lu, X. Chen, S. Y. Choong, S. Zhang, Y.-K. Chan, S. Glyn-Jones, G. D. Gamble, A. R. J. Phillips, and G. J. S. Cooper Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic Rats Mol. Pharmacol., December 1, 2006; 70(6): 2045 - 2051. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
